Nodofree (Dorzolamide Hydrochloride)

Dorzolamide blocks carbonic anhydrase enzymes in the ciliary body, reducing bicarbonate formation and aqueous humor secretion. The resulting decrease in fluid production lowers intra‑ocular pressure, which is essential in managing glaucoma and ocular hypertension.

The prescribed dosing regimen for Nodofree is determined by the treating ophthalmologist based on the patient’s condition, severity, and response to therapy. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for dorzolamide in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To request Nodofree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nodofree (dorzolamide) belongs to the carbonic anhydrase inhibitor class, which reduces aqueous humor production. Unlike prostaglandin analogues that increase outflow, dorzolamide works by decreasing fluid formation, offering an alternative mechanism that can be combined with other classes for additive pressure control.

Nodofree should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing to maintain product stability.

Nodofree is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, instill the prescribed number of drops, and close the eye gently for a few minutes. Contact lenses should be removed before dosing and re‑inserted after a short interval.

Serious risks include severe allergic reactions such as angioedema, corneal edema, persistent blurred vision, and rare systemic hypersensitivity. Patients should seek immediate medical attention if they experience significant eye pain, swelling, or sudden vision changes.

Patients with known hypersensitivity to dorzolamide or any component of the formulation should avoid Nodofree. Caution is also advised for individuals using systemic carbonic anhydrase inhibitors, those with severe ocular surface disease, or anyone for whom intra‑ocular pressure reduction could be harmful.